Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MHRA Issues Guidance On Recognizing And Reporting Medtech Software Adverse Events

Executive Summary

When it comes to medtech adverse events incidents may not always be obvious. This is especially the case with medical device software where indirect harm is the most likely outcome of an incident, the UK’s MHRA explains in new guidance.

You may also be interested in...



What Regulators Want To See From AI And Software-Based Devices

Experts in software and AI medtech regulation from the UK’s MHRA have outlined the questions that device developers should seek to answer when preparing for the regulatory process.

UK MHRA Gives CE-Marked Devices More Breathing Space In GB

The long-awaited extension of the UK MHRA’s standstill period for CE-marked devices circulating on the Great Britain market was announced in late April, offering new transition deadlines that go beyond the one extra year promised by the agency in fall 2022. Industry is studying the implications.

UK Updates Guidance To Reflect EU Medtech Extensions - Pledges Focus On Agility, Innovation

The EU’s decision to extend the Medical Device Regulation transition periods for legacy medical device directives products will be mirrored in the UK, which also continues to evolve its post-Brexit medtech regulatory system.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147930

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel